107 related articles for article (PubMed ID: 28667033)
1. Percent cPRA (Calculated Panel Reactive Antibody) Value Predicts Percent of Positive Platelet Crossmatches.
Pandey S; Rosenbaum E; Cottler-Fox M; Harville TO
Ann Clin Lab Sci; 2017 May; 47(3):315-318. PubMed ID: 28667033
[TBL] [Abstract][Full Text] [Related]
2. Flow Cytometric Panel-Reactive Antibody Results and the Ability to Find Transfusion-Compatible Platelets after Antibody-Desensitization for Allogeneic Bone Marrow Transplant.
Rosenbaum ER; Pandey S; Harville TO; Drobena GA; Cottler-Fox M
Ann Clin Lab Sci; 2016 Dec; 46(6):662-665. PubMed ID: 27993881
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
[TBL] [Abstract][Full Text] [Related]
4. A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions.
Revelli N; Villa MA; Olivero B; Bresciani S; Flores M; Marini M; Pizzi MN; Prati D; Rebulla P
Vox Sang; 2019 Jan; 114(1):73-78. PubMed ID: 30523641
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
6. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
8. Retrospective evaluation of flow cytometry as a platelet crossmatching procedure.
Gates K; MacPherson BR
Cytometry; 1994 Sep; 18(3):123-8. PubMed ID: 7813332
[TBL] [Abstract][Full Text] [Related]
9. Three patients highlighting potential pitfalls in platelet refractory testing.
Attieh M; Dent EA; Happney L; Roback JD; Alter DN; Barrette E; Then C; Sullivan HC
Transfusion; 2023 Apr; 63(4):888-892. PubMed ID: 36794568
[TBL] [Abstract][Full Text] [Related]
10. How do I … manage the platelet transfusion-refractory patient?
Juskewitch JE; Norgan AP; De Goey SR; Duellman PM; Wakefield LL; Gandhi MJ; Stubbs JR; Kreuter JD
Transfusion; 2017 Dec; 57(12):2828-2835. PubMed ID: 28960321
[TBL] [Abstract][Full Text] [Related]
11. Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens.
Belizaire R; Mack J; Kadauke S; Kim Y; Saidman S; Makar RS
Transfusion; 2019 Jul; 59(7):2256-2263. PubMed ID: 30980544
[TBL] [Abstract][Full Text] [Related]
12. Development of a Calculated Panel Reactive Antibody Web Service with Local Frequencies for Platelet Transfusion Refractoriness Risk Stratification.
Gordon WJ; Ainsworth L; Aronson S; Baronas J; Kaufman RM; Guleria I; Milford EL; Oates M; Paz RD; Yeung MY; Lane WJ
J Pathol Inform; 2019; 10():26. PubMed ID: 31463162
[TBL] [Abstract][Full Text] [Related]
13. False-negative solid-phase platelet crossmatch results due to prozone phenomenon.
Horton RK; Zuccarelli MD; Wakefield LL; DiGuardo MA; Gandhi MJ; Juskewitch JE
Transfusion; 2020 Dec; 60(12):3055-3059. PubMed ID: 33047855
[TBL] [Abstract][Full Text] [Related]
14. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD
JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444
[TBL] [Abstract][Full Text] [Related]
15. HLA-Mediated Platelet Refractoriness.
Schmidt AE; Refaai MA; Coppage M
Am J Clin Pathol; 2019 Mar; 151(4):353-363. PubMed ID: 30285067
[TBL] [Abstract][Full Text] [Related]
16. Platelet crossmatch testing for donor selection.
Slichter SJ
Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
[TBL] [Abstract][Full Text] [Related]
17. CPRA for allocation of kidneys in the US: More candidates ≥98% CPRA, lower positive crossmatch rates and improved transplant rates for sensitized patients.
Baxter-Lowe LA; Kucheryavaya A; Tyan D; Reinsmoen N
Hum Immunol; 2016 May; 77(5):395-402. PubMed ID: 27012168
[TBL] [Abstract][Full Text] [Related]
18. Successful management of alloimmunized patients by transfusing HLA compatible and crossmatched platelets.
Yung CH; Chow MP; Hu HY; Tzeng JL; Mou LL; Deng JM
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Apr; 47(4):228-36. PubMed ID: 1646671
[TBL] [Abstract][Full Text] [Related]
19. The alloimmunized patient: effective transfusion support and newer experimental approaches.
Pamphilon DH
Blood Coagul Fibrinolysis; 1992 Oct; 3(5):651-4. PubMed ID: 1450334
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric analysis in platelet crossmatching using a platelet suspension immunofluorescence test.
Skogen B; Christiansen D; Husebekk A
Transfusion; 1995 Oct; 35(10):832-6. PubMed ID: 7570913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
